CAP-CLIA Licensed Environment

Exome sequencing of a tumor/normal sample pair with automated tumor-associated SNV and small coding indel variant detection.

A targeted sequencing assay for 40 genes and gene hotspots that are recurrently mutated in acute myeloid leukemia and myelodysplastic syndrome using UMI-based targeted sequencing with the Agilent HaloplexHS

Custom exome sequencing with tumor/normal variant detection and known variant analysis in a patient-matched follow-up sample, as well as a limited germline analysis for incidental findings.

Tests are performed using targeted hybridization capture of tumor-derived genomic DNA coupled with next-generation sequencing (NGS). This approach enables deep, comprehensive coverage of all coding exons and key introns of ordered genes, and allows assessment of the molecular complexity of each DNA specimen, minimizing sampling bias even in cases of low DNA mass or quality.